Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S

Leah C. Wilson, Leslie A. Meyn, Mitchell D Creinin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: We investigated the safety and efficacy of using misoprostol and Dilapan-S™ hygroscopic cervical dilators to prepare the cervix for surgical abortion from 12 to 18 weeks of gestation in an outpatient office setting. Study design: This retrospective cohort study evaluated 554 consecutive women who had a surgical abortion from 12 to 18 weeks of gestation using a cervical preparation protocol at Planned Parenthood of Western Pennsylvania between September 2007 and September 2009. Lamicel® osmotic dilators were used for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women 14 to 18 weeks of gestation until September 2008 after which it was no longer available. New guidelines based on available literature included misoprostol 400 mcg vaginally for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women between 14 and 15 6/7 weeks of gestation, and Dilapan-S between 16 and 18 weeks of gestation. Cervical preparation was intended to allow rigid dilation, if necessary, to complete a same-day procedure. We evaluated the ability to complete the procedure on the same day with both protocols and frequency of adverse events. Results: A total of 239 and 168 women received a cervical preparation agent under the old and new protocols, respectively. Demographic characteristics were similar between study cohorts. All procedures in both groups were completed on the same day. Severe complications occurred in two women under the old protocol (excessive bleeding with transfer to hospital) and none with the new protocol. Conclusions: Early experience for same-day surgical abortion from 12 to 18 weeks of gestation in an outpatient setting using misoprostol and Dilapan-S for cervical preparation is positive in regard to efficacy and safety.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalContraception
Volume83
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Misoprostol
Pregnancy
Cohort Studies
Outpatients
Safety
dilapan
Cervix Uteri
Dilatation
Retrospective Studies
Demography
Guidelines
Hemorrhage

Keywords

  • Abortion
  • Cervical preparation
  • Cervix
  • Dilapan
  • Lamicel
  • Misoprostol

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S. / Wilson, Leah C.; Meyn, Leslie A.; Creinin, Mitchell D.

In: Contraception, Vol. 83, No. 6, 06.2011, p. 511-516.

Research output: Contribution to journalArticle

@article{0cd18e916d924813a61b07c9b7e1c5b0,
title = "Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S",
abstract = "Background: We investigated the safety and efficacy of using misoprostol and Dilapan-S™ hygroscopic cervical dilators to prepare the cervix for surgical abortion from 12 to 18 weeks of gestation in an outpatient office setting. Study design: This retrospective cohort study evaluated 554 consecutive women who had a surgical abortion from 12 to 18 weeks of gestation using a cervical preparation protocol at Planned Parenthood of Western Pennsylvania between September 2007 and September 2009. Lamicel{\circledR} osmotic dilators were used for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women 14 to 18 weeks of gestation until September 2008 after which it was no longer available. New guidelines based on available literature included misoprostol 400 mcg vaginally for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women between 14 and 15 6/7 weeks of gestation, and Dilapan-S between 16 and 18 weeks of gestation. Cervical preparation was intended to allow rigid dilation, if necessary, to complete a same-day procedure. We evaluated the ability to complete the procedure on the same day with both protocols and frequency of adverse events. Results: A total of 239 and 168 women received a cervical preparation agent under the old and new protocols, respectively. Demographic characteristics were similar between study cohorts. All procedures in both groups were completed on the same day. Severe complications occurred in two women under the old protocol (excessive bleeding with transfer to hospital) and none with the new protocol. Conclusions: Early experience for same-day surgical abortion from 12 to 18 weeks of gestation in an outpatient setting using misoprostol and Dilapan-S for cervical preparation is positive in regard to efficacy and safety.",
keywords = "Abortion, Cervical preparation, Cervix, Dilapan, Lamicel, Misoprostol",
author = "Wilson, {Leah C.} and Meyn, {Leslie A.} and Creinin, {Mitchell D}",
year = "2011",
month = "6",
doi = "10.1016/j.contraception.2010.10.004",
language = "English (US)",
volume = "83",
pages = "511--516",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S

AU - Wilson, Leah C.

AU - Meyn, Leslie A.

AU - Creinin, Mitchell D

PY - 2011/6

Y1 - 2011/6

N2 - Background: We investigated the safety and efficacy of using misoprostol and Dilapan-S™ hygroscopic cervical dilators to prepare the cervix for surgical abortion from 12 to 18 weeks of gestation in an outpatient office setting. Study design: This retrospective cohort study evaluated 554 consecutive women who had a surgical abortion from 12 to 18 weeks of gestation using a cervical preparation protocol at Planned Parenthood of Western Pennsylvania between September 2007 and September 2009. Lamicel® osmotic dilators were used for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women 14 to 18 weeks of gestation until September 2008 after which it was no longer available. New guidelines based on available literature included misoprostol 400 mcg vaginally for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women between 14 and 15 6/7 weeks of gestation, and Dilapan-S between 16 and 18 weeks of gestation. Cervical preparation was intended to allow rigid dilation, if necessary, to complete a same-day procedure. We evaluated the ability to complete the procedure on the same day with both protocols and frequency of adverse events. Results: A total of 239 and 168 women received a cervical preparation agent under the old and new protocols, respectively. Demographic characteristics were similar between study cohorts. All procedures in both groups were completed on the same day. Severe complications occurred in two women under the old protocol (excessive bleeding with transfer to hospital) and none with the new protocol. Conclusions: Early experience for same-day surgical abortion from 12 to 18 weeks of gestation in an outpatient setting using misoprostol and Dilapan-S for cervical preparation is positive in regard to efficacy and safety.

AB - Background: We investigated the safety and efficacy of using misoprostol and Dilapan-S™ hygroscopic cervical dilators to prepare the cervix for surgical abortion from 12 to 18 weeks of gestation in an outpatient office setting. Study design: This retrospective cohort study evaluated 554 consecutive women who had a surgical abortion from 12 to 18 weeks of gestation using a cervical preparation protocol at Planned Parenthood of Western Pennsylvania between September 2007 and September 2009. Lamicel® osmotic dilators were used for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women 14 to 18 weeks of gestation until September 2008 after which it was no longer available. New guidelines based on available literature included misoprostol 400 mcg vaginally for nulliparous women between 12 1/7 and 13 6/7 weeks of gestation and all women between 14 and 15 6/7 weeks of gestation, and Dilapan-S between 16 and 18 weeks of gestation. Cervical preparation was intended to allow rigid dilation, if necessary, to complete a same-day procedure. We evaluated the ability to complete the procedure on the same day with both protocols and frequency of adverse events. Results: A total of 239 and 168 women received a cervical preparation agent under the old and new protocols, respectively. Demographic characteristics were similar between study cohorts. All procedures in both groups were completed on the same day. Severe complications occurred in two women under the old protocol (excessive bleeding with transfer to hospital) and none with the new protocol. Conclusions: Early experience for same-day surgical abortion from 12 to 18 weeks of gestation in an outpatient setting using misoprostol and Dilapan-S for cervical preparation is positive in regard to efficacy and safety.

KW - Abortion

KW - Cervical preparation

KW - Cervix

KW - Dilapan

KW - Lamicel

KW - Misoprostol

UR - http://www.scopus.com/inward/record.url?scp=79955935100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955935100&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2010.10.004

DO - 10.1016/j.contraception.2010.10.004

M3 - Article

C2 - 21570547

AN - SCOPUS:79955935100

VL - 83

SP - 511

EP - 516

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -